Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 7/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28679540 | 0.88 | TAS2R14 (0.46) | SYKRORCKDRRXFP1CDK1 | |
| SCHEMBL20577982 | 0.85 | GRM4 (0.42) | SYKRORCKDRRXFP1BRAF | |
| SCHEMBL20577989 | 0.73 | CBLB (0.50) | RXFP1 | |
| SCHEMBL20578168 | 0.73 | MAPK14 (0.41) | RORCKDR | |
| SCHEMBL20578026 | 0.72 | KDR (0.51) | RORCKDRRXFP1BRAF | |
| SCHEMBL20577966 | 0.72 | KDR (0.43) | RORCKDRBRAF | |
| SCHEMBL28664640 | 0.71 | RXFP1 (0.45) | SYKKDRRXFP1BRAF | |
| SCHEMBL20577951 | 0.71 | RXFP1 (0.54) | SYKKDRRXFP1BRAF | |
| SCHEMBL16524048 | 0.71 | STK17B (0.48) | SYKRORCCDK1 | |
| SCHEMBL13244157 | 0.70 | GRM4 (0.51) | SYKRORCTTKEGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071543-B | Pyridine derivatives inhibiting RAF kinase and vascular endothelial growth factor receptor, process for their preparation, pharmaceutical compositions containing them and their use | 三进制药株式会社 | 2021-07-16 | — | — | CN | disclosed |